The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Key challenges that remain in the diagnosis of AL amyloidosis
In this video, Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses the challenges in diagnosing light chain (AL) amyloidosis, emphasizing that it remains a rare and often underdiagnosed condition. Dr Lebel highlights the importance of raising awareness among various specialties, including family physicians, nephrologists, and cardiologists, as AL amyloidosis presents with multisystem involvement and symptoms that can easily be misattributed to other conditions. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
